Biochemical basics of imaging in positron emission tomography in oncology. Part 2

This article provides an overview of the main literature data of biochemical basics and the clinical application of positron emission tomography, one of the promising technologies of radiation imaging in oncology.
In the current part we discuss in detail the biokinetics of radiopharmaceuticals used to visualize various groups of tumor cells receptors. These include angiogenesis markers - RGD peptides, ligands for somatostatin receptors, agents for sex hormone imaging, ligands for prostate-specific membrane antigen and to activating EGFR mutant kinase. It contains results of studies that were dedicated to search for optimal modifications of these radiopharmaceuticals to increase diagnostic efficiency, their comparative analysis is carried out, the results of their use in cancer research and development prospects in this industry are highlighted.

PET/CT, radiopharmaceuticals, receptor imaging, receptor ligands, RGD-peptides, NET, DOTA-conjugated peptides, DOTATATE, DOTATOC, DOTANOC, PSMA ligands, estrogen receptors imaging, FES, sex hormone imaging, EGFR

1. Brooks P.C., Strömblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin αvβ3. Cell. 1996; 85 (5): 683–693. https://doi.org/10.1016/s0092-8674(00)81235-0

2. Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 Integrin Antagonists: A New Class of Tracers for Tumor Targeting. J. Nucl. Med. 1999; 40: 1061–1071.

3. Chen H., Niu G., Wu H., Chen X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin αvβ3. Theranostics. 2016; 6 (1): 78–92. https://doi.org/10.7150/thno.13242

4. Karen A., Kurdziel M.D., Lindenberg L., Choyke P.L. Oncologic angiogenesis imaging in the clinic – how and why. Imaging Med. 2011; 3 (4): 445–457.

5. Haubner R., Wester H.J., Reuning U., SenekowitschSchmidtke R., Diefenbach B., Kessler H., Stöcklin G., Schwaiger M. Radiolabeled αvβ3 integrin antagonists: A new class of tracers for tumor targeting. J. Nucl. Med. 1999; 40 (6): 1061–1071.

6. Niu G., Chen X. RGD PET: From Lesion Detection to Therapy Response Monitoring. J. Nucl. Med. 2015; 57 (4): 501–502. https://doi.org/10.2967/jnumed.115.168278

7. Zhang H., Liu N., Gao S., Hu X., Zhao W., Tao R., Chen Z., Zheng J., Sun X., Xu L., Li W., Yu J., Yuan S. Can an 18F-AlF-NOTA-PRGD2 PET/CT scan predict the treatment sensitivity of concurrent chemoradiotherapy in patients with newly diagnosed glioblastoma? J. Nucl. Med. 2016; 57: 524–529. https://doi.org/10.2967/jnumed.115.165514

8. Cescato R., Schulz S., Waser B., Eltschinger V., Rivier J.E., Wester H.J., Culler M., Ginj M., Liu Q., Schonbrunn A., Reubi J.C. Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 2006; 47 (3): 502–511. https://doi.org/10.1111/bph.12551

9. Sollini M., Erba P.A., Fraternali A. PET and PET/CT with 68Gallium-labeled somatostatin analogues in non GEPNETs tumors. Sci. Wld J. 2014; 2014: Article ID 194123. https://doi.org/10.1155/2014/194123

10. Hofland L.J., Lamberts S.W. The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr. Rev. 2003; 24: 28–47. https://doi.org/10.1210/er.2000-0001

11. Virgolini I., Ambrosini V., Bomanji J.B., Baum R.P., Fanti S., Gabriel M., Papathanasiou N.D., Pepe G., Oyen W., De Cristoforo C., Chiti A. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur. J. Nucl. Med. Mol. Imaging. 2010; 37: 2004–2010. https://doi.org/10.1007/s00259-010-1512-3

12. Geijer H., Breimer L.H. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J. Nucl. Med. Mol. Imaging. 2013; 40 (11): 1770–1780. https://doi.org/10.1007/s00259-013-2482-z

13. Fani M., Nicolas G.P., Wild D. Somatostatin Receptor Antagonists for Imaging and Therapy. J. Nucl. Med. 2017; 58 (Suppl. 2): 61S–66S. https://doi.org/10.2967/jnumed.116.186783

14. Chan D.L.H., Pavlakis N., Schembri G.P., Bernard E.J., Hsiao E., Hayes A., Barnes T., Diakos C., Khasraw M., Samra J., Eslick E., Roach P.J., Clarke S.J., Bailey D.L. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017; 7 (5): 1149–1158. https://doi.org/10.7150/thno.18068

15. Hindié E. The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors. Theranostics. 2017; 7 (5): 1159–1163. https://doi.org/10.7150/thno.19588

16. Fani M., Nicolas G.P., Wild D. Somatostatin receptor antagonists for imaging and therapy. J. Nucl. Med. 2017; 58: 61S–66S. https://doi.org/10.2967/jnumed.116.186783

17. Fani M., Peitl P.K., Velikyan I. Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms. Pharmaceuticals. 2017; 10 (1): 30. https://doi.org/10.3390/ph10010030

18. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J., Mäcke H.R., Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proceedings of the National Academy of Sciences. 2006; 103 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103

19. Lenzo N., Cardaci J., Meyrick D., Henderson A., Crouch J., Yeo S., Turner H. Lu-177 OPS-201 (satareotide) Trial for Metastatic Neuroendocrine Tumour. Доступно по: http://theranostics.com.au/wp-content/uploads/2016/05/Lu-177-OPS-201-Satareotide-Trial-for-Metastatic-Neuroendocrine-Tumours.pdf. Ссылка активна на 01.07.2019г.

20. Rylova S.N., Stoykow C., Del Pozzo L., Abiraj K., Tamma M.L., Kiefer Y., Fani M., Maecke H.R. The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model. PLoS One. 2018; 13 (4): e0195802. https://doi.org/10.1371/journal.pone.0195802

21. Ginj M., Zhang H., Waser B., Cescato R., Wild D., Wang X., Erchegyi J., Rivier J.R. Mäcke H.R, Reubi J.C. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl. Acad. Sci. USA. 2006; 3 (44): 16436–16441. https://doi.org/10.1073/pnas.0607761103

22. Nicolas G.P., Schreiter N., Kaul F., Uiters J., Bouterfa H., Kaufmann J., Wild D. Sensitivity comparison of 68GaOPS202 and 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors: a prospec tive phase II imaging study. J. Nuclear Med. 2017; 59 (6): 915–921. https://doi.org/10.2967/jnumed.117.199760

23. Kunz P.L. Carcinoid and neuroendocrine tumors: building on success. J. Clin. Oncol. 2015; 33: 1855–1863. https://doi.org/10.1200/JCO.2014.60.2532

24. Endocrinology: National guidelines. Brief Edition / Eds I.I.Dedova, G.A. Melnichenko. M.: GEOTAR-Media, 2013. 752 p. (In Russian)

25. Bozkurt M.F., Virgolini I., Balogova S., Beheshti M., Rubello D., Decristoforo C., Ambrosini V., Kjaer A., Delgado-Bolton R., Kunikowska J., Oyen W.J.G., Chiti A., Giammarile F., Sundin A., Fanti S. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTAconjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (9): 1588–1601. https://doi.org/10.1007/s00259-017-3728-y

26. Khayum M.A., Doorduin J. Glaudemans A.W.J.M., Dierckx R.A.J.O. , E.F.J., de Vries R.A.J.O. PET and SPECT of Neurobiological Systems. Chapter 14. Berlin; Heidelberg: Springer-Verlag, 2014.

27. Liu C., Gong C., Liu S., Zhang Y., Zhang Y., Xu X., Yuan H., Wang B., Yang Z. 18F-FES PET/CT influences the staging and management of newly diagnosed Oestrogen Receptor positive Breast Cancer Patients: A Retrospective Comparative Study with 18F-FDG PET/CT. J. Nucl. Med. 2019; 60 (1): 596.

28. Sun Y., Yang Z., Zhang Y., Xue J., Wang M., Shi W., Zhu B., Hu S., Yao Z., Pan H., Zhang Y. The preliminary study of 16α-[18F]fluoroestradiol PET/CT in assisting the individualized treatment decisions of breast cancer patients. PLoS ONE. 2015; 10 (1): e0116341. https://doi.org/10.1371/journal.pone.0116341

29. Nienhuis H.H., van Kruchten M., Elias S.G., Glaudemans A.W.J.M., de Vries E.F.J., Bongaerts A.H.H., Schröder C.P., de Vries E.G.E., Hospers G.A.P. 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients. J. Nucl. Med. 2018; 59 (8): 1212–1218. https://doi.org/10.2967/jnumed.117.198846

30. Gong C., Yang Z., Sun Y., Zhang J., Zheng C., Wang L., Zhang Y., Xue J., Yao Z., Pan H., Wang B., Zhang Y. A preliminary study of 18F-FES PET/CT in predicting metastatic breast cancer in patients receiving docetaxel or fulvestrant with docetaxel. Scientific Reports. 2017; 7: 6584. https://doi.org/10.1038/s41598-017-06903-8

31. Mertan F.V., Lindenberg L., Choyke P.L., Turkbey B. PET imaging of recurrent and metastatic prostate cancer with novel tracers. Future Oncol. 2016; 12 (21): 2463–2477. https://doi.org/10.2217/fon-2016-0270

32. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 1987; C (7): 27–935.

33. Afshar-Oromieh A., Babich J.W., Giesel C.K.F.L., Eisenhut M., Kopka K., Haberkorn U. The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer. J Nucl Med. 2016;57:79S–89S. https://doi.org/10.2967/jnumed.115.170720

34. Giesel F.L., Kesch C., Yun M., Cardinale J., Haberkorn U., Kopka K., Kratochwil C., Hadaschik B.A. 18F-PSMA-1007 PET/CT detects micrometastases in a patient with biochemically recurrent prostate cancer. Clin. Genitourin Cancer. 2017; 15 (3): 497–499. https://doi.org/10.1016/j.clgc.2016.12.029

35. Leontyev A.V., Rubtsova N.A., Khalimon A.I., Kuliev M.T., Pylova I.V., Lazutina T.N., Khamadeeva G.F., Alekseev B.Ya., Kostin A.A., Kaprin A.D. Application of radiolabeled ligands to the prostate-specific membrane antigen for determine localization of biochemical recurrence of prostate cancer by PET/CT (literature review). Medical Visualization. 2018; 22 (3): 81–97. https://doi.org/10.24835/1607-0763-2018-3-81-97 (In Russian)

36. Afshar-Oromieh A., Holland-Letz T., Giesel F.L., Kratochwil C., Mier W., Haufe S., Debus N., Eder M., Eisenhut M., Schäfer M., Neels O., Hohenfellner M., Kopka K., Kauczor H.U., Debus J., Haberkorn U. Diagnostic performance of (68Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: Evaluation in 1007 patients. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (8): 1258–1268. https://doi.org/10.1007/s00259-017-3711-7

37. Schwenck J., Rempp H., Reischl G., Kruck S., Stenzl A., Nikolaou K., Pfannenberg C., la Fougère C. Comparison of 68Ga-labelled PSMA-11 and 11C-choline in the detection of prostate cancer metastases by PET/CT. Eur. J. Nucl. Med. Mol. Imaging. 2017; 44 (1): 92–101. https://doi.org/10.1007/s00259-016-3490-6

38. Roach P.J., Francis R., Emmett L., Hsiao E., Kneebone A., Hruby G., Eade T., Nguyen Q.A., Thompson B.D., Cusick T., McCarthy M., Tang C., Ho B., Stricker P.D., Scott A.M. The impact of 68Ga-PSMA PET/CT on management intent in prostate cancer: Results of an Australian prospective multicenter study. J. Nucl. Med. 2018; 59 (1): 82–88. https://doi.org/10.2967/jnumed.117.197160

39. Albisinni S., Artigas C., Aoun F., Biaou I., Grosman J., Gil T., Hawaux E., Limani K., Otte F.X., Peltier A., Sideris S., Sirtaine N., Flamen P., van Velthoven R. Clinical impact of 68Ga-prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in patients with prostate cancer with rising prostate-specific antigen after treatment with curative intent: Preliminary analysis of a multidisciplinary approach. BJU Int. 2017; 120 (2): 197–203. https://doi.org/10.1111/bju.13739

40. Veliev E.I., Tomilov A.A., Bogdanov A.B. Salvage lymph node dissection in patients with oligometastatic recurrence of prostate cancer confirmed by PET-CT. Cancer Urology. 2018; 14 (4): 79–86. https://doi.org/10.17650/1726-9776-2018-14-4-79-86 (In Russian)

41. Kabasakal L., Demirci E., Ocak M. et al. Evaluation of PSMA PET/CT imaging using a 68Ga- HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl. Med. Commun. 2015; C-36 (6): 582–587.

42. Giesel F.L., Knorr K., Spohn F. et al. Detection efficacy of [18F]PSMA-1007 PET/CT in 251 Patients with biochemical recurrence after radical prostatectomy. J. Nucl. Med. 2018; 60 (3): 362–368. https://doi.org/10.2967/jnumed.118.212233

43. Sakaeva D.D., Gordiev M.G. Epidermal growth factor receptor as target of molecular-targeted therapy in patients with primary non-small cell lung cancer. Malignant Tumours.2016; 3: 54–59. https://doi.org/10.18027/2224-5057-2016-3-54-59 (In Russian)

44. Gorbunova V.A., Artamonova E.V., Breder V.V., Laktionov K.K., Moiseenko F.V., Reutova E.V. et al. Practical guidelines for the treatment of non-small cell lung cancer. Malignant tumors: Practical guidelines for RUSSCO; 3s2, 2017 (Volume 7). p. 28–42. (In Russian)

45. Sun X., Xiao Z.,Chen G. et al. A PET imaging approach for determining EGFR mutation status for improved lung cancer patient management. Sci Transl. Med. 2018: 7: 10 (431). https://doi.org/10.1126/scitranslmed.aan8840